A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth.

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Starting on a weight loss medication has helped Joie Armstrong prioritize caring for herself, including finding more ...

Jewelry shops are seeing an increase in business due to the popularity of weight loss drugs. Women using drugs, like Ozempic, are heading to jewelers in droves to size down their rings. Van Guilder’s ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...